-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
On October 15th, Jax Pharmaceuticals announced that the company's self-developed CD73 monoclonal antibody JAB-BX102 clinical trial application has been approved by the FDA, and Phase 1/2a clinical trials will be carried out in the United States
CD73 is a rate-limiting enzyme that catalyzes the conversion of adenosine monophosphate (AMP) to adenosine.
JAB-BX102 is a CD73 monoclonal antibody independently developed by Jacos Pharmaceuticals
(The original text has been deleted)
Reference materials:
[1] Jacosi CD73 monoclonal antibody JAB-BX102 obtained new drug clinical trial approval in the United States.